Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysis

TC Lee, M Kaouache, SA Grover - Canadian Medical Association …, 2018 - cmajopen.ca
Background: Evolocumab, a proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor,
has been shown to reduce low-density lipoprotein levels by up to 60%. Despite the absence …

Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial

SA Murphy, TR Pedersen, ZA Gaciong, R Ceska… - JAMA …, 2019 - jamanetwork.com
Importance The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol
and first cardiovascular events in the Further Cardiovascular Outcomes Research With …

Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting

M Korman, T Wislřff - European Heart Journal–Cardiovascular …, 2018 - academic.oup.com
Aims Despite the success of statins, there remains unmet clinical need in cardiovascular
disease (CVD) prevention. New proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Long-term evolocumab in patients with established atherosclerotic cardiovascular disease

ML O'Donoghue, RP Giugliano, SD Wiviott, D Atar… - Circulation, 2022 - Am Heart Assoc
Background: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9
Inhibition in Subjects With Elevated Risk), the proprotein convertase subtilisin-kexin type 9 …

[HTML][HTML] Evolocumab's long-term mortality risk unclear due to shortened follow-up of FOURIER

FH van Bruggen, HJ Luijendijk - American Journal of Cardiovascular …, 2022 - Springer
Abstract The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 inhibition
in Subjects with Elevated Risk) trial was conducted to study cardiovascular outcomes of …

Reduction in total cardiovascular events with the PCSK9 inhibitor evolocumab in patients with cardiovascular disease in the FOURIER trial

SA Murphy, TR Pedersen, ZA Gaciong, R Ceska… - Circulation, 2017 - Am Heart Assoc
Introduction: Intensive LDL-C lowering with the PCSK9i evolocumab (EvoMab) significantly
reduced the risk of major vascular events in pts with stable atherosclerotic disease treated …

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the …

RP Giugliano, TR Pedersen, JG Park, GM De Ferrari… - The Lancet, 2017 - thelancet.com
Background LDL cholesterol is a well established risk factor for atherosclerotic
cardiovascular disease. How much one should or safely can lower this risk factor remains …

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial

SR Shah, MF Uddin, N Lateef, AM Dharani… - Journal of Community …, 2017 - Taylor & Francis
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a protease that binds to the
extracellular compartment of the LDL receptor, hence, targeting the LDL receptor to the …

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in …

N Katsiki, VG Athyros, DP Mikhailidis… - Metabolism-Clinical …, 2017 - metabolismjournal.com
Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have been shown to
decrease low-density lipoprotein cholesterol (LDL-C) levels by about 60% on top of statin …

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

MS Sabatine, RP Giugliano, A Keech, N Honarpour… - American heart …, 2016 - Elsevier
Background Despite current therapies, patients with vascular disease remain at high risk for
major adverse cardiovascular events. Low-density lipoprotein cholesterol is a well …